" Editor's note: This story was updated on Dec. 30 with a CDC update.
Dec. 17, 2014 -- Flu season is in full force, according to the CDC, which is reporting widespread disease activity in 36 states for the wee"...
Flublok Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Flublok (Influenza Vaccine) is a vaccine used to prevent seasonal influenza in adults 18 to 49 years of age. Common side effects of Flublok are injection-site pain, headache, fatigue, and muscle pain.
Flublok is administered by intramuscular injection through 0.5mL single dose vials. Flublok is not currently known to interact with other medications. Tell your doctor all medications you use. The safety and effectiveness of Flublok has not been established in pregnant women or nursing mothers.
Our Flublok (Influenza Vaccine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Flublok FDA Prescribing Information: Side Effects
The most common ( ≥ 10%) injection-site reaction was pain ( > 37%); the most common ( ≥ 10%) solicited systemic adverse reactions were headache ( > 15%), fatigue ( > 15%) and myalgia ( > 11%).
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to rates in the clinical studies of another vaccine and may not reflect the rates observed in clinical practice.
Flublok has been administered to and safety data collected from 2497 adults 18 through 49 years of age enrolled in two randomized, placebo-controlled clinical trials (1, 2). In both studies local (injection site) and systemic adverse reactions were solicited with the use of a memory aid for 7 days following vaccination. Unsolicited adverse reactions were collected for 28 days post-vaccination and Serious Adverse Events (SAEs) were collected for 6 months post-vaccination via clinic visit or telephone follow up on Day 28, telephone follow up on Day 180, or by spontaneous reporting.
In a clinical trial (Study 1, Table 1) that included 2,344 subjects randomized to receive Flublok and 2,304 subjects randomized to receive saline placebo, the mean age of participants was 32.5 years, 59% were female, and 67% were Caucasian (see Clinical Studies).
Table 1: Frequency of Solicited Injection Site
Reactions and Systemic Adverse Reactions within 7 Days of Administration of
Flublok or Placebo in Adults 18-49 Years of Age, Study 1, Total Vaccinated
|Local Adverse Reactions||%||%|
|Systemic Adverse Reactions||%||%|
|Fever‡||< 1||< 1|
|NOTE: Data based on the most severe response reported by
subjects. Results > 1% reported to nearest whole percent; results > 0 but
< 1 reported as < 1%.
‡ Fever defined as ≥ 99.8°F (37.7°C).
1 Total Vaccinated Cohort is defined as all randomized subjects who received study vaccine according to the treatment actually received and who provided data.
2 Study 1 is registered as NCT00539981 under the National Clinical Trials registry.
3 Denominators for Study 1: The total number of enrolled subjects was 2344 in the Flublok group and 2304 in the placebo group. For all categories except fever, the number of subjects with missing values was 72 in the Flublok group and 73 in the Placebo group so that these denominators are 2272 and 2231 respectively. For fever, 89 Flublok recipients and 104 Placebo recipients were missing data, making these denominators 2255 and 2200 respectively.
Across trials, through 6 months post vaccination, two deaths were reported, one in a Flublok recipient and one in a placebo recipient. Both deaths occurred more than 28 days following vaccination and neither was considered vaccine-related. SAEs were reported by 32 Flublok recipients and 35 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related to the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No specific cause was identified. The patient recovered.
In Study 1, the most frequent unsolicited adverse events, occurring in 1%-2% of subjects, were nasopharyngitis, upper respiratory infection, headache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea.
No postmarketing safety data are available for Flublok.
1. Treanor JJ, El Sahly HM, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine, 2011, Vol. 13, 29, pp. 7733-7739.
2. Treanor JJ, Schiff GM, Hayden FG, et.al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007, Vol. 297, pp. 1577-1582.
Read the entire FDA prescribing information for Flublok (Influenza Vaccine for Intramuscular Injection) »
Additional Flublok Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.